RT Journal Article
SR Electronic
T1 Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.03.20239863
DO 10.1101/2020.12.03.20239863
A1 Martin Modrák
A1 Paul-Christian Bürkner
A1 Tomáš Sieger
A1 Tomáš Slisz
A1 Martina Vašáková
A1 Grigorij Mesežnikov
A1 Luis Fernando Casas-Mendez
A1 Jaromír Vajter
A1 Jan Táborský
A1 Viktor Kubricht
A1 Daniel Suk
A1 Jan Horejsek
A1 Martin Jedlička
A1 Adriana Mifková
A1 Adam Jaroš
A1 Miroslav Kubiska
A1 Jana Váchalová
A1 Robin Šín
A1 Markéta Veverková
A1 Zbyšek Pospíšil
A1 Julie Vohryzková
A1 Rebeka Pokrievková
A1 Kristián Hrušák
A1 Kristína Christozova
A1 Vianey Leos-Barajas
A1 Karel Fišer
A1 Tomáš Hyánek
YR 2020
UL http://medrxiv.org/content/early/2020/12/04/2020.12.03.20239863.abstract
AB We collected a multi-centric retrospective dataset of patients (N = 213) who were admitted to ten hospitals in Czech Republic and tested positive for SARS-CoV-2. The dataset contains baseline patient characteristics, breathing support required, pharmacological treatment received and multiple markers on daily resolution. Patients in the dataset were treated with hydroxychloroquine (N = 108), azithromycin (N = 72), favipiravir (N = 9), convalescent plasma (N = 7), dexamethasone (N = 4) and remdesivir (N = 3), often in combination. Most patients were admitted during the first wave of the epidemic. To explore association between treatments and patient outcomes we performed multiverse analysis, observing how the conclusions change between defensible choices of statistical model, predictors included in the model and other analytical degrees of freedom. Weak evidence to constrain the potential efficacy of azithromycin and favipiravir can be extracted from the data. Additionally, we performed external validation of several proposed prognostic models for Covid-19 severity showing that they mostly perform unsatisfactorily on our dataset.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by ELIXIR CZ research infrastructure project (MEYS Grant No: LM2018131) including access to computing and storage facilities.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical committees of General University Hospital, Hospital Novy Jicin, Motol University Hospital, Thomayer Hospital, University Hospital Vinohrady, Military Hospital Olomouc, Na Homolce Hospital, University Hospital in Pilsen, Horovice Hospital, Jihlava Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, if legal obligations under GDPR can be met. The data are not publicly available due to privacy restrictions. We will be happy to arrange to run any analytical code locally and share the results, provided the code and the results do not leak personal information.